









市場行情
/
股票
/
nasdaq-sgmo
/

Sangamo Therapeutics Inc

SGMO

0.460USD

+0.014+3.09%

收盤 12/22, 16:00（美東）報價延遲15分鐘

148.19M總市值

虧損本益比TTM



Sangamo Therapeutics Inc

0.460

+0.014+3.09%

概覽公司財務分析

概覽

公司

財務

分析

關於 Sangamo Therapeutics Inc 公司

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Sangamo Therapeutics Inc簡介



公司代碼SGMO

公司名稱Sangamo Therapeutics Inc

上市日期Apr 06, 2000

CEOMacrae (Alexander D)

員工數量183

證券類型Ordinary Share

年結日Apr 06

公司地址501 Canal Blvd.

城市RICHMOND

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94084

電話15109706000

網址https://www.sangamo.com/

公司代碼SGMO

上市日期Apr 06, 2000

CEOMacrae (Alexander D)

Sangamo Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Willoughby

Chief Legal Officer & Corporate Secretary

302.87K

-0.67%

Dr. Gregory Davis, Ph.D.

Head of Research & Technology

197.63K

-0.36%

Ms. Margaret A. Horn, J.D.

Independent Director

76.40K

+48.64%

Dr. Courtney Beers, Ph.D.

Independent Director

76.40K

+48.64%

Dr. Karen Lesley Smith, M.D., Ph.D.

Independent Director

Dr. John H. Markels, Ph.D.

Independent Director

Ms. Louise Wilkie

Investor Relations

Ms. H. Stewart Parker

Independent Chairman of the Board

Ms. Nathalie Dubois- Stringfellow, Ph.D.

Chief Development Officer

Mr. Robert F. Carey

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Scott B. Willoughby

Chief Legal Officer & Corporate Secretary

302.87K

-0.67%

Dr. Gregory Davis, Ph.D.

Head of Research & Technology

197.63K

-0.36%

Ms. Margaret A. Horn, J.D.

Independent Director

76.40K

+48.64%

Dr. Courtney Beers, Ph.D.

Independent Director

76.40K

+48.64%

Dr. Karen Lesley Smith, M.D., Ph.D.

Independent Director

Dr. John H. Markels, Ph.D.

Independent Director

收入明細

FY2024

FY2023

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

57.80M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月21日週五

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

3.45%

Renaissance Technologies LLC

3.03%

Two Sigma Investments, LP

1.38%

BlackRock Institutional Trust Company, N.A.

1.35%

GSA Capital Partners LLP

1.09%

其他

89.70%

持股股東

佔比

The Vanguard Group, Inc.

3.45%

Renaissance Technologies LLC

3.03%

Two Sigma Investments, LP

1.38%

BlackRock Institutional Trust Company, N.A.

1.35%

GSA Capital Partners LLP

1.09%

其他

89.70%

股東類型

持股股東

佔比

Investment Advisor

8.22%

Hedge Fund

6.55%

Investment Advisor/Hedge Fund

2.89%

Research Firm

1.04%

Corporation

0.97%

Individual Investor

0.95%

其他

79.37%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

319

55.42M

16.47%

-39.56M

2025Q2

349

61.18M

25.54%

-60.51M

2025Q1

404

58.78M

24.86%

-65.68M

2024Q4

408

67.57M

32.39%

-54.70M

2024Q3

411

61.90M

29.72%

-75.37M

2024Q2

422

105.29M

52.02%

-52.38M

2024Q1

424

122.66M

61.96%

-20.13M

2023Q4

430

104.60M

58.76%

-36.84M

2023Q3

436

126.62M

71.56%

-23.29M

2023Q2

448

137.28M

80.06%

-15.05M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.37M

3.11%

Jun 30, 2025

Renaissance Technologies LLC

6.84M

2.27%

+3.67M

+115.88%

Jun 30, 2025

Two Sigma Investments, LP

2.08M

0.69%

+397.81K

+23.60%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.18M

1.38%

-371.02K

-8.16%

Jun 30, 2025

GSA Capital Partners LLP

2.25M

0.74%

+1.28M

+132.40%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.33M

0.77%

+48.83K

+2.14%

Jun 30, 2025

Biogen Inc

3.25M

1.08%

-11.40M

-77.82%

Aug 14, 2024

Susquehanna International Group, LLP

773.27K

0.26%

-1.04M

-57.27%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

1.28M

0.42%

+183.97K

+16.76%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.62%

iShares Neuroscience and Healthcare ETF

0.28%

Global X Genomics & Biotechnology ETF

0.2%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Micro-Cap ETF

ProShares Hedge Replication ETF

Schwab U.S. Small-Cap ETF

State Street SPDR S&P Kensho New Econ Comp ETF

State Street SPDR S&P Biotech ETF

Global X Russell 2000 Covered Call ETF

Invesco NASDAQ Future Gen 200 ETF

佔比0.62%

iShares Neuroscience and Healthcare ETF

佔比0.28%

Global X Genomics & Biotechnology ETF

佔比0.2%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.02%

iShares Micro-Cap ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

Schwab U.S. Small-Cap ETF

佔比0%

State Street SPDR S&P Kensho New Econ Comp ETF

佔比0%

State Street SPDR S&P Biotech ETF

佔比0%

Global X Russell 2000 Covered Call ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Sangamo Therapeutics Inc的前五大股東是誰？



Sangamo Therapeutics Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：9.37M
佔總股份比例：3.11%。
Renaissance Technologies LLC
持有股份：6.84M
佔總股份比例：2.27%。
Two Sigma Investments, LP
持有股份：2.08M
佔總股份比例：0.69%。
BlackRock Institutional Trust Company, N.A.
持有股份：4.18M
佔總股份比例：1.38%。
GSA Capital Partners LLP
持有股份：2.25M
佔總股份比例：0.74%。